<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099187</url>
  </required_header>
  <id_info>
    <org_study_id>MA39189</org_study_id>
    <secondary_id>2016-002744-17</secondary_id>
    <nct_id>NCT03099187</nct_id>
  </id_info>
  <brief_title>A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease</brief_title>
  <official_title>Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pirfenidone in
      participants with fibrosing interstitial lung disease (ILD) who cannot be classified with
      moderate or high confidence into any other category of fibrosing ILD by multidisciplinary
      team (MDT) review (&quot;unclassifiable&quot; ILD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2017</start_date>
  <completion_date type="Anticipated">January 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Rate of decline in FVC will be measured in mL by daily handheld spirometer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted FVC</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>FVC will be measured in mL by daily handheld spirometer as well as by spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Change in FVC of &gt;5% During Clinic Visits</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Categorical change in FVC will be measured both by daily spirometry as well as by spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Change in FVC of &gt;10% During Clinic Visits</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Categorical change in FVC will be measured both by daily spirometry as well as by spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute Walk Distance (6MWD)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Comparison of 6-minute walk distance before beginning and after completing study therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in University of California, San Diego-Shortness of Breath Questionnaire Score</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores is calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score in Leicester Cough Questionnaire Score</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) are calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) is also calculated by adding the domain scores together. Higher scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cough Visual Analog Scale (VAS) Score</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>SGRQ is a health related quality of life questionnaire consisting of 40 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Non-elective Hospitalization, Both Respiratory and all Cause</measure>
    <time_frame>Up to Week 91</time_frame>
    <description>Participants with non-elective hospitalization will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Investigator-reported Acute Exacerbations</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Percentage of participants with acute exacerbation will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Investigator-reported Acute Exacerbations</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>Time to first investigator reported acute exacerbations from start of treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>PFS is defined as the time to the first occurrence of a &gt;10% absolute decline in percent predicted FVC, a &gt;50 m decline of 6MWD, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline (Day 1) to Week 24</time_frame>
    <description>PFS is defined as the time to the first occurrence of a &gt;10% absolute decline in percent predicted FVC, non-elective respiratory hospitalization, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death From any Cause</measure>
    <time_frame>Up to Week 91</time_frame>
    <description>Time to first documented death from start of treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death from Respiratory Diseases</measure>
    <time_frame>Up to Week 91</time_frame>
    <description>Time to first documented death due to respiratory diseases from start of treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline (Day 1) up to Week 80</time_frame>
    <description>An adverse events is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Reductions and Treatment Interruptions</measure>
    <time_frame>From administration of the first dose of study drug to Week 24</time_frame>
    <description>Number of participants with dose reduction and treatment interruptions will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECG)</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>Number of participants with abnormalities in ECG will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Withdrawn from Trial Treatment or Trial Discontinuations</measure>
    <time_frame>Up to Week 91</time_frame>
    <description>Number of participants withdrawn from trial treatment or trial discontinuations will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lung Diseases, Interstitial</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone 267 mg capsules three times in a day.</description>
    <arm_group_label>Pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules three times in a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18-85 years

          -  Confirmed fibrosing ILD which, following multidisciplinary team review, cannot be
             classified with either high or moderate confidence as a specific idiopathic
             interstitial pneumonia or other defined ILD

          -  Progressive disease as considered by the investigator as participants deterioration
             within the last 6 months, which is defined as a rate of decline in forced vital
             capacity (FVC) &gt;5% or a significant symptomatic worsening not due to cardiac,
             pulmonary vascular or other causes

          -  Extent of fibrosis &gt;10% on high-resolution computed tomography

          -  Forced vital capacity &gt;= 45% of predicted value

          -  Diffusing capacity of the lung for carbon monoxide (DLco) &gt;= 30% of predicted value

          -  Forced expiratory volume in 1 second/FVC ratio &gt;= 0.7

          -  Able to do 6-minute walk distance (6MWD) &gt;= 150 meters

          -  For women of childbearing potential: agreement to remain abstinent or use a
             non-hormonal or hormonal contraceptive method with a failure rate of &lt; 1% per year
             during the treatment period and for at least 90 days after the last dose of
             pirfenidone

          -  For men, agreement to remain abstinent or use contraceptive measures, and agreement to
             refrain from donating sperm

        Exclusion Criteria:

          -  Diagnosis with moderate or high confidence of nonspecific interstitial pneumonia and
             any ILD with an identifiable cause such as connective tissue disease-ILD, chronic
             hypersensitivity pneumonitis, or others

          -  Diagnosis of idiopathic pulmonary fibrosis independent of the confidence level

          -  History of unstable angina or myocardial infarction during the previous 6 months

          -  Treatment with high dose systemic corticosteroids, or any immunosuppressant other than
             mycophenolate mofetil/acid (MMF), at any time within the 4 weeks of the screening
             period. Participants being treated with MMF should be on a stable dose that is
             expected to remain stable throughout the trial and was started at least 3 months prior
             to screening

          -  Participants previously treated with pirfenidone or nintedanib

          -  Participants treated with N-acetyl-cysteine for fibrotic lung disease, at any time
             within the 4 weeks of the screening period

          -  Drug treatment for any type of pulmonary hypertension

          -  Participation in a trial of an investigational medicinal product within the last 4
             weeks

          -  Significant other organ co-morbidity including hepatic or renal impairment

          -  Predicted life expectancy &lt; 12 months or on an active transplant waiting list

          -  Use of any tobacco product in the 12 weeks prior to the start of screening, or any
             unwillingness to abstain from their use through to the Follow-up Visit

          -  Illicit drug or alcohol abuse within 12 months prior to screening

          -  Planned major surgery during the trial

          -  Hypersensitivity to the active substance or to any of the excipients of pirfenidone

          -  History of angioedema

          -  Concomitant use of fluvoxamine

          -  Clinical evidence of any active infection

          -  Any history of hepatic impairment, elevation of transaminase enzymes, or liver
             function test results as: Total bilirubin above the upper limit of normal (ULN),
             Aspartate aminotransferase or alanine aminotransferase &gt;1.5 × ULN, and Alkaline
             phosphatase &gt;2.0 × ULN

          -  Creatinine clearance &lt; 30 milliliter (mL) per minute, calculated using the
             Cockcroft-Gault formula

          -  Any serious medical condition, clinically significant abnormality on an
             Electrocardiogram (ECG) at screening, or laboratory test results

          -  An ECG with a heart rate corrected QT interval using Fridericia's formula as &gt;= 500
             milliseconds at screening, or a family or personal history of long QT syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: MA39189 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital; Respiratory Department; Respiratory Department</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northside Heart and Lung</name>
      <address>
        <city>Nundah</city>
        <state>Queensland</state>
        <zip>4012</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital; Respiratory Clinical Trials Unit, Thoracic Medicine</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bowen Centre Austin Health; Institute for Breathing and Sleep</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahan</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital; Advanced Lung Disease Unit</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital University of British Colambia Division of Hematology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUM Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec (Hôpital Laval)</name>
      <address>
        <city>Ste. Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno-Bohunice; Klinika Tuberkulozy A Respiracnich Chorob</name>
      <address>
        <city>Brno</city>
        <zip>639 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc; Pneumologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Lungemedicinsk Afd. LUB</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital, Lungemedicinsk Afdeling</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital, Lungemedicinsk Afdeling J</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH; Pneumologie</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evang. Lungenklinik Berlin Klinik für Pneumologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik der Justus-Liebig-Universität; Innere Medizin</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens &quot;Attikon&quot;, B' University Pulmonary Clinic</name>
      <address>
        <city>Chaidari</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklio, Pulmonary Clinic</name>
      <address>
        <city>Heraklio</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincents University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka; Pulmonary Clinic</name>
      <address>
        <city>Beer Sheba</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center; Pulmonary Institute</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center; Pulmonary Inst.</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center; Pulmonary Institute</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center; Pulmonary Dept</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beilinson Medical Center; Pulmonary Inst.</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>7661041</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni-Pierantoni; U.O. Pneumologia</name>
      <address>
        <city>Forlì</city>
        <state>Emilia-Romagna</state>
        <zip>47121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico A.Gemelli Università Cattolica del Sacro Cuore; Pneumologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe; U.O. di Pneumologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Ospedali Riuniti Umberto I -G.M. Lancisi-G. Salesi Ancona; SOD Pneumologia</name>
      <address>
        <city>Torrette Di Ancona</city>
        <state>Marche</state>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria San Luigi Gonzaga di Orbassano; Ambulatorio per le Malattie Rare del Polmone</name>
      <address>
        <city>Orbassano (TO)</city>
        <state>Piemonte</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Vittorio Emanuele; Centro per la cura delle Malattie Rare del Polmone</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedali Riuniti; Villa Sofia-Cervello di Palermo; U. O. Pneumologia 2 - Padiglione B</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi; SOD Pneumologia e Fisiopatologia Toracico Polmonare</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne;Klinika Alergologii i Pneumonologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny Nr 1 im.N.Barlickiego Oddzial Kliniczny Pneumonologii i Alergologii</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infante D. Pedro; Servico de Pneumologia</name>
      <address>
        <city>Aveiro</city>
        <zip>3814-501</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HUC; Servico de Pneumologia A</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pulido Valente; Servico de Pneumologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1796-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Joao; Servico de Pneumologia</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHVNG/E_Unidade 1; Servico de Pneumologia</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge ; Servicio de Neumologia</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08097</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de neumologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa; Servicio de Neumologia</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos - Servicio de Neumologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Neumologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital; Respiratory Department</name>
      <address>
        <city>Bristol</city>
        <zip>BS10-5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust; Respiratory Department</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary; Respiratory Department</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital (Wonford)</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospital; Respiratory Medicine</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital; Respiratory Department</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital; North West Lung Research Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

